Shares of GSK (GSK) are falling after a Centers for Disease Control and Prevention (CDC) committee shifted its recommendation on Respiratory Syncytial Virus (RSV) vaccination dosages.

Yahoo Finance reporter Anjalee Khemlani joins Morning Brief to break down this latest development for GSK and what the CDC announcement could mean for the company moving forward.

For more expert insight and the latest market action, click here to watch this full episode of Morning Brief.

This post was written by Nicholas Jacobino.

Video Transcript

And let's also take a look at GSK because the CDC here shifting its recommendation for ours.

The vaccines.

We're seeing the stock under a bit of pressure.

That's right.

So the based on the data that was presented to an advisory panel this week, the CDC and the advisory panel recommended that those that are older on the older side of, uh, the age gap for seniors.

So those who are, say, 65 and older to 70 years old, that's going to be sort of recommended if they have other severe diseases.

But then those that are on the older side of that range will have to get just one dose.

And so that shrinks the market a little bit for companies like GSK, Pfizer, as well as those are the three companies on the market.

We also saw Moderna drop on its results, showing much lower efficacy than the other two companies when it comes to protection over two seasons.

So all of that playing a role in sort of what was supposed to be projected.

As you know, this 10 billion market opportunity could be a lot less for all these companies combined